Market revenue in 2023 | USD 183.6 million |
Market revenue in 2030 | USD 317.0 million |
Growth rate | 8.1% (CAGR from 2023 to 2030) |
Largest segment | Toxicology testing |
Fastest growing segment | Bioanalysis and DMPK studies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology |
Key market players worldwide | Eurofins Scientific SE, Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc, Intertek Group PLC, Labcorp Holdings Inc, Crown Bioscience, SGA |
Toxicology testing was the largest segment with a revenue share of 22.49% in 2023. Horizon Databook has segmented the Japan preclinical cro market based on bioanalysis and dmpk studies, toxicology testing, compound management, chemistry, safety pharmacology covering the revenue growth of each sub-segment from 2018 to 2030.
The growing pharmaceutical industry in Japan is contributing to the increasing demand for preclinical trial outsourcing. There has been a significant increase in the number of preclinical trials being conducted in the country as the Japanese government is undertaking steps to offer regulatory support and promote preclinical trials in the country. This is expected to stimulate the market for preclinical services as preclinical testing requires to be conducted in proximity to central development centers.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account